Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CDK9 | P50750 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SCN1A | P35498 | 1/20 | 0.52 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.52 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12366200 | 0.91 | ALDH1A1 (0.62) | EPHX2MAPTHTTTP53SMN1; SMN2 | |
| SCHEMBL9976374 | 0.85 | EPHX2 (0.55) | EPHX2L3MBTL1TP53EPHX1TSHR | |
| SCHEMBL12366199 | 0.84 | MGLL (0.62) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL27640149 | 0.82 | EPHX2 (0.55) | EPHX2MAPTL3MBTL1HTTTP53 | |
| SCHEMBL12366106 | 0.80 | ALOX5 (0.58) | TSHRSMN1; SMN2GAAKDM4ECYP3A4 | |
| SCHEMBL1689206 | 0.80 | EPHX2 (0.68) | EPHX2MAPTL3MBTL1HTTTP53 | |
| SCHEMBL2688879 | 0.78 | EPHX2 (0.61) | EPHX2MAPTL3MBTL1HTTTP53 | |
| SCHEMBL12618851 | 0.78 | EPHX2 (0.58) | EPHX2L3MBTL1HTTSMN1; SMN2MEN1 | |
| SCHEMBL3342586 | 0.78 | L3MBTL1 (0.80) | EPHX2MAPTL3MBTL1HTTSMN1; SMN2 | |
| SCHEMBL2470801 | 0.77 | L3MBTL1 (0.66) | EPHX2MAPTL3MBTL1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420856-B2 | Process for preparation of teriflunomide | ALEMBIC LTD. (ID) | 2013-04-16 | — | — | US | disclosed |
| US-8389757-B2 | Process for preparing teriflunomide | ALEMBIC LTD. (IN) | 2013-03-05 | — | — | US | disclosed |
| US-7998986-B2 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20110105795-A1 | PROCESS FOR PREPARATION OF TERIFLUNOMIDE | Akembic Ltd. (IN) | 2011-05-05 | — | — | US | disclosed |
| US-20110092727-A1 | PROCESS FOR PREPARING TERIFLUNOMIDE | ALEMBIC LIMITED (IN) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105795-A1 | PROCESS FOR PREPARATION OF TERIFLUNOMIDE | CYP3A5, CYP51A1, CYP2F1 | EPHX2 1320/4885MAPT 1862/4885L3MBTL1 4725/4885 |
| US-20110092727-A1 | PROCESS FOR PREPARING TERIFLUNOMIDE | FIP1L1, CYP2F1, FDPS | EPHX2 888/4885MAPT 2578/4885L3MBTL1 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.